569 studies found for:    "Keratoconjunctivitis sicca"
Show Display Options
Rank Status Study
1 Completed
Has Results
Dry Eye Assessment and Management: Feasibility Study
Conditions: Dry Eye Syndromes;   Keratoconjunctivitis Sicca
Interventions: Drug: Omega-3 EFA Supplement;   Drug: Olive Oil
2 Completed Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome
Conditions: Dry Eye Syndromes;   Keratoconjunctivitis Sicca
Interventions: Drug: AT01;   Drug: AT02;   Drug: AT03;   Drug: AT04
3 Completed
Has Results
Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca
Condition: Keratoconjunctivitis Sicca
Interventions: Drug: CF101;   Drug: Placebo
4 Completed Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca
Condition: Keratoconjunctivitis Sicca
Intervention: Drug: Pimecrolimus
5 Active, not recruiting Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
Conditions: Keratoconjunctivitis Sicca;   Dry Eye Disease
Interventions: Drug: OTX-101 0.05%;   Drug: OTX-101 0.09%;   Drug: Vehicle
6 Completed Effects of Conventional Dry Eye Treatments on the Ocular Surface Response to Low Humidity Environment in Patients With Keratoconjunctivitis Sicca
Conditions: Keratoconjunctivitis Sicca;   Dry Eye Syndrome
Intervention: Drug: dexamethasone, artificial tears
7 Completed Safety and Efficacy Study of SAR 1118 to Treat Dry Eye
Conditions: Dry Eye;   Keratoconjunctivitis Sicca
Intervention: Drug: Lifitegrast
8 Recruiting Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Conditions: Dry Eye Syndromes;   Keratoconjunctivitis Sicca
Interventions: Drug: KPI-121 0.25% Ophthalmic Suspension;   Drug: Vehicle of KPI-121 0.25% Ophthalmic Suspension
9 Completed Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Conditions: Dry Eye Syndromes;   Keratoconjunctivitis Sicca
Interventions: Drug: KPI-121;   Drug: Placebo
10 Recruiting Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease
Conditions: Dry Eye Syndromes;   Keratoconjunctivitis Sicca
Interventions: Drug: KPI-121 0.25% Ophthalmic Suspension;   Drug: Vehicle of KPI-121 0.25% Ophthalmic Suspension
11 Completed Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis
Conditions: Dry Eye Disease;   Keratoconjunctivitis Sicca
Interventions: Drug: Lotemax;   Drug: Restasis
12 Active, not recruiting Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
Condition: Keratoconjunctivitis Sicca
Interventions: Drug: cyclosporine;   Drug: vehicle of OTX-101
13 Completed Lotemax® Gel 0.5% and Restasis 0.05% in Subjects With Mild or Moderate Keratoconjunctivitis Sicca
Condition: Keratoconjunctivitis Sicca
Interventions: Drug: Lotemax Gel + Restasis;   Drug: Lotemax Gel;   Drug: Restasis
14 Completed Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops
Conditions: Keratoconjunctivitis Sicca;   Sjogren's Syndrome
Intervention: Drug: Cyclosporin A
15 Completed Efficacy and Safety Study of Nutritional Supplements for Treatments of Dry Eye
Condition: Keratoconjunctivitis Sicca
Interventions: Dietary Supplement: Hydroeye;   Other: Inactive Capsule
16 Completed Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye
Conditions: Dry Eye Syndromes;   Keratoconjunctivitis Sicca
Interventions: Drug: rebamipide 2% ophthalmic suspension;   Drug: placebo eye drops
17 Completed Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Subjects With Dry Eye - Effects on Central Cornea
Conditions: Keratoconjunctivitis Sicca;   Dry Eye
Interventions: Drug: rebamipide 2% ophthalmic suspension;   Drug: placebo eye drops
18 Completed Study of Rebamipide Eye Drops to Treat Dry Eye
Condition: Keratoconjunctivitis Sicca
Intervention: Drug: Rebamipide
19 Completed Study of Rebamipide Eye Drops to Treat Dry Eye
Condition: Keratoconjunctivitis Sicca
Intervention: Drug: Rebamipide
20 Completed
Has Results
Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye
Conditions: Dry Eye Syndromes;   Keratoconjunctivitis Sicca
Interventions: Drug: carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD);   Drug: sodium hyaluronate 0.18% (VISMED® Multi)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years